BTIG analyst Ryan Zimmerman maintained a Buy rating on Tactile Systems Technology (TCMD – Research Report) yesterday and set a price target of $19.00. The company’s shares opened today at $13.94.
Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Vericel, and Stryker. According to TipRanks, Zimmerman has an average return of 8.9% and a 47.46% success rate on recommended stocks.
Currently, the analyst consensus on Tactile Systems Technology is a Strong Buy with an average price target of $24.00.
See today’s best-performing stocks on TipRanks >>
Based on Tactile Systems Technology’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $69.59 million and a net profit of $22.3 million. In comparison, last year the company earned a revenue of $65.26 million and had a GAAP net loss of $2.28 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tactile Systems Technology (TCMD) Company Description:
Tactile Systems Technology, Inc. is a medical technology company. It develops and provides innovative medical devices for the treatment of chronic diseases at home. The company focus on advancing the standard of care in treating chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. It possesses a platform to deliver at-home healthcare solutions throughout the United States. Tactile Systems Technology was founded on January 30, 1995 and is headquartered in Minneapolis, MN.
Read More on TCMD:
- Tactile Systems management to meet virtually with BTIG
- Tactile Systems price target lowered to $19 from $22 at BTIG
- Tactile Systems cuts Fy23 revenue view to $273M-$277M from $274M-$278M
- Tactile Systems reports Q3 adjusted EBITDA $7.7M vs. $7.2M last year
- Tactile Systems price target lowered to $23 from $30 at Piper Sandler
